Sirion Therapeutics Announces Availability of Zirgan(TM) (ganciclovir ophthalmic gel) 0.15% for Ocular Herpes
4/26/2010 8:47:09 AM
TAMPA, Fla., April 26 /PRNewswire/ -- Sirion Therapeutics, Inc., a privately held ophthalmic biopharmaceutical company, announced today that Zirgan™ (ganciclovir ophthalmic gel) 0.15% is now commercially available. Zirgan™, which was approved by the U.S. Food and Drug Administration in September 2009, is a topical ophthalmic antiviral indicated for the treatment of acute herpetic keratitis (dendritic ulcers).
comments powered by